Overview of ACKR1/DARC-Associated Neutropenia (ADAN) and the Potential Clinical Implications of This Condition in Clinical Practice
H Al-Qayyim1*, L Balakrishnan1*, P Sriskandarajah1
1Department of Haematology, Guy’s Hospital, London, SE1 9RT, United Kingdom.
*These authors contributed equally to this work.
*Corresponding Author: Priya Sriskandarajah, Department of Haematology, Guy’s Hospital, London, SE1 9RT, United Kingdom. E-mail: priya.sriskandarajah@nhs.net
https://doi.org/10.58624/SVOAMR.2025.03.007
Received: April 05, 2025
Published: April 30, 2025
Citation: Al-Qayyim H, Balakrishnan L, Sriskandarajah P. Overview of ACKR1/DARC-Associated Neutropenia (ADAN) and the Potential Clinical Implications of This Condition in Clinical Practice. SVOA Medical Research 2025, 3:2, 62-69. doi: 10.58624/SVOAMR.2025.03.007
Abstract
Neutropenia is one of the most common referrals to the general haematology clinic, and is particularly prevalent in patients of African background. This is unsurprising as these patients often have ACKR1/DARC-associated neutropenia (ADAN), previously known as Benign Ethnic Neutropenia (BEN). To date, ADAN has not been known to have an impact on underlying bone marrow function and is generally monitored. However, recent studies do suggest that ADAN could be implicated in non-haematological conditions. Furthermore, ADAN has been shown to impact delivery of treatment for other disease areas including psychiatric disorders and cancers. Our review article focuses on the pathophysiology of ADAN and importantly on its potential influence on other disorders, both directly and indirectly. Finally, we discuss how research may be warranted to better our understanding of this condition.
Keywords: Neutropenia; Duffy; Inflammation; Malignancy